《HemaSphere》研究:线粒体更活跃或与慢性髓性白血病治疗反应不佳相关
More active mitochondria may help chronic myeloid leukemia cells withstand treatment
《HemaSphere》一项研究分析 120 例慢性期慢性髓性白血病患者的线粒体 DNA 突变,发现线粒体功能更活跃或与一线 imatinib 治疗反应较差相关。
Researchers in Adelaide and Singapore have uncovered new clues as to why some people with chronic myeloid leukemia (CML) respond better to treatment than others, finding that mitochondrial function in cancer cells could be targeted to improve responses.
Published in HemaSphere, the study, led by Dr. Ilaria Pagani and Associate Professor David Ross, examined mitochondrial DNA mutations in 120 patients with chronic-phase CML, revealing a relationship between mitochondrial genetics, cancer cell metabolism and responses to treatment.
Fitter mitochondria linked to poorer responses
Pagani says that mitochondria may play a much greater role in determining treatment success than previously thought.
"We found that mitochondrial DNA mutations aren't simply incidental findings—they appear to be linked to how well patients respond to frontline treatment," Pagani said.
"The cells from patients with poorer responses appeared to have fitter, more active mitochondria. This may provide them with the energy and flexibility they need to survive treatment pressure."
Targeting leukemia cells' energy supply
Chronic myeloid leukemia is typically treated with tyrosine kinase inhibitors (TKIs), such as imatinib, which have brought patients' survival rates close to those of the general population. While most patients respond well to these therapies, some achieve slower or less effective responses, and researchers have long sought to understand why.
The study found that leukemia cells from poorer responders relied more heavily on mitochondrial energy production, revealing a potential vulnerability that could be targeted therapeutically.
To explore this possibility, researchers treated CML stem and progenitor cells with a mitochondrial inhibitor. In preclinical experiments, the treatment reduced the cells' ability to grow and survive. When combined with imatinib, the effect was even stronger, almost eliminating colony formation entirely.
"While mitochondrial inhibitors aren't currently used to treat chronic myeloid leukemia, our findings show proof of concept that disrupting the way these cancer cells generate energy may improve responses to existing TKI therapies," Ross said.
"More broadly, this work provides a new framework for using mitochondrial genetics to identify metabolic vulnerabilities, not only in CML but potentially in other cancers treated with targeted therapies."
"By combining genetic and metabolic information, we may eventually be able to identify patients who are less likely to respond well to imatinib and develop more personalized treatment approaches."
Shared data reveal mitochondrial clues
The study brought together complementary expertise and resources from three countries. The team at the University of Glasgow shared experimental protocols that were established at SAHMRI, while researchers in Singapore contributed their expertise and a unique single-cell dataset. Pagani recognized that the dataset could be examined from a new perspective by screening it for mitochondrial DNA mutations.
"This discovery was only possible because researchers were willing to share their methods, data and expertise," Pagani said.
"The Glasgow protocols allowed us to study how patient cells produced energy, while the Singapore data allowed us to examine mitochondrial mutations in thousands of individual cells. Bringing these different pieces together gave us a much clearer picture of why some leukemia cells respond poorly to imatinib."
More information
Ilaria S. Pagani et al., Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia, HemaSphere (2026). DOI: 10.1002/hem3.70429
Key medical concepts
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: More active mitochondria may help chronic myeloid leukemia cells withstand treatment (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-mitochondria-chronic-myeloid-leukemia-cells.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com